What's more, the dysregulation of TNF and IER3 pathways in PM‐associated epilepsy suggests therapeutic potential for targeted immunomodulation (e.g., TNF signaling blockade), which may mitigate seizure susceptibility in high‐risk patients. This evidence concerns the gene IER3 and epilepsy.